Backed by a £680,000 grant from Leeds Hospitals Charity, the study is jointly led by academics and clinicians from the University of Leeds and Leeds Teaching Hospitals NHS Trust
Interchangeable biosimilars to Prolia and Xgeva target osteoporosis and cancer-related bone complications in a $5 billion U.S. market
Multi-year CDMO partnership combines AI-led virtual development, precision chemistry and GMP manufacturing to accelerate five high-science APIs across regulated markets
He brings extensive cross-functional expertise built through leadership roles
71-year-old high-risk patient with atrial fibrillation and ventricular tachycardia discharged next day
The SirPAD trial marks a significant milestone in vascular intervention, positioning MagicTouch PTA as a promising future alternative for PAD treatment
Its a major breakthrough for women’s ovarian cancer care in Europe
The study targets patients with refractory, unresectable microsatellite-stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC)
This marks a meaningful step in the company's continued expansion in the region
Benzonatate is a non-narcotic antitussive that numbs stretch receptors in the respiratory tract
Subscribe To Our Newsletter & Stay Updated
